Journal article
Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials
Abstract
AIMS: It is unknown whether cardioversion of atrial fibrillation causes thromboembolic events or is a risk marker. To assess causality, we examined the temporal pattern of thromboembolism in patients having cardioversion.
METHODS AND RESULTS: We studied patients randomized to aspirin or aspirin plus clopidogrel in the ACTIVE trials, comparing the thromboembolic rate in the peri-cardioversion period (30 days before until 30 days after) to the …
Authors
McIntyre WF; Connolly SJ; Wang J; Masiero S; Benz AP; Conen D; Wong JA; Beresh H; Healey JS
Journal
European Heart Journal, Vol. 40, No. 36, pp. 3026–3032
Publisher
Oxford University Press (OUP)
Publication Date
September 21, 2019
DOI
10.1093/eurheartj/ehz521
ISSN
0195-668X